Your Medication Isn't Working. Your Genes May Be Why.

CYP2D6 is one of the most important drug-metabolizing enzymes in your body. It breaks down antidepressants, opioids, beta-blockers for heart rhythm, and pain medications. If this enzyme works normally, medications reach their therapeutic window and then clear at the right rate. Your mood stabilizes, your pain drops, your heart rhythm smooths out.

But CYP2D6 comes in many versions. The *4, *10, and *17 variants reduce enzyme activity significantly. Poor metabolizers, who carry two non-functional copies, make up roughly 7 to 10 percent of people with European ancestry. In poor metabolizers, drugs accumulate to toxic levels because the body can’t clear them fast enough. At the same time, ultra-rapid metabolizers, who have gene duplications, process these same drugs so quickly they never reach therapeutic levels at all.

If you’re a poor metabolizer on a standard dose of an antidepressant, you might experience dizziness, nausea, sexual dysfunction, or emotional blunting at doses that would barely touch someone with normal metabolism. If you’re ultra-rapid, you might feel nothing at all, even at high doses, because the drug clears before it can work.

CYP2C19 metabolizes clopidogrel, a blood thinner prescribed after heart stents, plus SSRIs and other antidepressants. The gene has poor-metabolizer variants (*2, *3) and ultra-rapid variants (*17). Roughly 2 to 15 percent of people carry poor-metabolizer variants, depending on ancestry; Asian populations have higher rates of ultra-rapid variants.

Here’s where it gets critical: clopidogrel is a prodrug. It’s inactive until CYP2C19 converts it into its active form inside your liver. If you’re a poor metabolizer, your liver can’t activate the drug, and you get zero antiplatelet benefit despite taking it daily after a stent. You’re at high risk of blood clot formation and stent thrombosis. Meanwhile, ultra-rapid metabolizers activate it so fast they develop excessive bleeding risk.

People with CYP2C19 poor-metabolizer variants who are prescribed clopidogrel often experience clotting events and are told they ‘failed’ on the drug, when in fact their genetics made it impossible for the drug to work. The solution isn’t switching drugs; it’s switching to a different antiplatelet that doesn’t require CYP2C19 activation.

CYP2C9 metabolizes warfarin, the most commonly prescribed blood thinner, plus NSAIDs and some statins. The *2 and *3 variants reduce enzyme activity. Roughly 5 to 10 percent of people with European ancestry carry poor-metabolizer variants, though prevalence varies by population.

Warfarin has a narrow therapeutic window. Too little and you don’t prevent clots; too much and you bleed internally. In poor metabolizers of CYP2C9, standard warfarin doses accumulate to dangerous levels because the drug clears slowly. The result is spontaneous bruising, nosebleeds, blood in urine, and sometimes life-threatening bleeding events. Many people on standard warfarin doses have experienced hospitalization for bleeding; testing could have prevented it.

Someone with a CYP2C9 poor-metabolizer variant might need 30 to 50 percent of the standard warfarin dose to stay safely in therapeutic range. Without genetic testing, doctors increase doses based on INR levels, not understanding that the underlying problem is slow metabolism, not inadequate dosing.

VKORC1 encodes vitamin K epoxide reductase, the enzyme that warfarin actually targets. The gene itself doesn’t metabolize the drug; it is the drug’s target. The -1639G>A variant changes how sensitive this enzyme is to warfarin. The A allele, found in roughly 40 percent of people with European ancestry, produces a protein that’s highly sensitive to warfarin’s effects.

People with the A allele require lower warfarin doses because their vitamin K recycling is more easily blocked by the drug. At standard dosing, they overshoot into the therapeutic range, increasing bleeding risk. Conversely, people without the A allele need higher doses to achieve the same anticoagulant effect because their enzyme is less sensitive.

When you start warfarin, your dose is guessed based on body weight and age. The truth is that VKORC1 variants are one of the biggest predictors of the dose you actually need. Someone with a sensitive VKORC1 variant on a ‘standard’ warfarin dose is being overanticoagulated from day one, silently at risk for a bleeding event.

SLCO1B1 encodes a transporter protein that pulls statins into liver cells, where they work. The *5 variant (rs4149056) reduces transporter function. Roughly 15 percent of people carry at least one copy of this variant, and it’s more common in certain populations.

Statins like simvastatin, pravastatin, and lovastatin depend on SLCO1B1 to enter hepatocytes. If your transporter is weak, statins can’t get into liver cells efficiently. Instead of working where they’re supposed to, statins circulate in your bloodstream at higher concentrations, increasing the risk of muscle pain, weakness, and rhabdomyolysis. People with SLCO1B1 variants who take simvastatin at standard doses often experience debilitating muscle pain and are told to stop the drug, when a lower dose would have been safe and effective.

You might think ‘just switch to another statin,’ but some statins like atorvastatin depend less on SLCO1B1 and are safer in people with this variant. Without testing, people end up cycling through different statins, experiencing side effects unnecessarily.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, used for autoimmune conditions, leukemia, and transplant rejection. The gene has several variants that reduce enzyme function. Roughly 0.3 percent of people are complete poor metabolizers (two non-functional copies), but up to 10 percent are intermediate metabolizers with one non-functional copy.

Poor metabolizers of TPMT accumulate toxic thiopurine metabolites and face severe bone marrow suppression, infections, and sometimes death, even at standard doses. This is why TPMT testing is legally recommended before starting thiopurines in most countries. Intermediate metabolizers need dose reductions. Standard dosing assumes normal metabolism; if you’re deficient, the drug becomes a poison.

Someone with TPMT poor-metabolizer status could experience sudden onset of severe anemia, low white blood cell counts, and life-threatening infections at the exact dose that would be safe for someone with normal metabolism. The side effects are severe enough that TPMT is one of the few genes where genetic testing is practically mandatory before prescribing.